Moviprep powder for the preparation of oral solution is a laxative drug. Oral ingestion of a solution of electrolytes based on macrogol causes mild diarrhea, which results in rapid emptying of the colon contents. Macrogol-3350, sodium sulfate and ascorbic acid have an osmotic effect, causing a laxative effect. Macrogol-3350 increases the amount of feces, which leads to increased intestinal motility. Electrolytes that are part of the drug, as well as additional fluid intake prevent the violation of water and electrolyte balance.
Powder for preparing a solution for ingestion from white to yellow color, with a characteristic lemon smell (sachet A): macrogol 3350 100 g, sodium sulfate 7.5 g, sodium chloride 2.691 g, potassium chloride 1.015 g. Auxiliary substances: aspartame - 0.233 g, Acesulfame potassium - 0.117 g, lemon flavor V3938-1 N1 - 0.34 g. Powder for preparing a solution for oral administration from white to light brown (sachet B): ascorbic acid 4.7 g, sodium ascorbate 5.9 g.
Preparation for diagnostic studies (endoscopic, X-ray and other studies of the intestine) and surgical interventions that require emptying the intestines.
Use in renal dysfunction Care for severe renal failure (QC <30 ml / min), use in children It is contraindicated in children under 18 years. Use in elderly patients Elderly patients should be used under medical supervision. Elderly patients who are debilitated or exhausted in patients with various concomitant diseases, patients prone to aspiration or regurgitation, with impaired consciousness, especially if the drug is administered through a nasogastric tube, the drug should be used be under medical control. The prepared solution of Moviprep does not replace a regular fluid intake, therefore it is necessary to maintain an adequate level of fluid in the body. In exhausted debilitated patients, patients with various concomitant diseases, with clinically significant renal impairment,Arrhythmia and the risk of electrolyte imbalance should consider the need to determine the level of electrolytes at baseline and after treatment, assess kidney function and perform an ECG study. In rare cases, serious arrhythmia has been observed, including atrial fibrillation associated with the use of ionic osmotic laxatives to prepare the intestines. These phenomena occur predominantly in patients with existing cardiac risk factors and electrolyte imbalance. If patients experience any symptoms indicating arrhythmias or changes in water / electrolyte balance (for example, edema, shortness of breath, fatigue, heart failure), the level of electrolytes in the blood plasma, perform an ECG and conduct adequate treatment of all identified abnormalities. If a patient has symptoms such as marked flatulence, bloating Ivot, abdominal pain or any other reactions that impede the further administration of the drug, it is necessary to slow down or temporarily suspend the administration of the drug and consult a doctor. When treating patients who follow a diet with a controlled sodium content, it should be borne in mind that the drug contains 56.2 mmol of absorbable sodium per 1 liter of solution. When treating patients with renal impairment or patients who follow a diet with a controlled potassium content, it should be noted that contains 14.2 mmol of potassium per 1 liter of solution. The effect on the ability to drive vehicles and mechanismsIn the course of the preparation course for medical manipulations, the Moviprep preparation is recommended in zderzhatsya from driving and other mechanisms.
Use during pregnancy and lactation
Experience with the use of the drug Moviprep during pregnancy and during breastfeeding is limited. Moviprep should be used only in cases where the intended benefit to the mother outweighs the potential risk to the fetus or child (consult a doctor).
Dosage and administration
Inside To prepare one liter of the preparation solution, the contents of one sachet A and one sachet B should be dissolved in a small amount of water, then the volume of the solution should be made up to one liter of water.To prepare a second liter of a solution of the drug, the contents of the remaining second sachet A and the second sachet B should be dissolved in a small amount of water, then the volume of the solution should be made up to one liter of water. The total dose is 2 liters of the solution Moviprep. The solution can be taken once (2 liters in the evening before or 2 liters in the morning on the day of the procedure) or divided into two doses (1 l in the evening and 1 l in the morning on the day of the procedure). Before surgery, take once 2 liters of a solution of the drug the night before. The prepared solution should be drunk within 1-2 hours. During the course of preparation, it is strongly recommended to additionally consume 1 liter of other liquid (water, broth, fruit juice without pulp, soft drinks, tea, coffee without milk). With a separate (1 liter the night before and 1 liter in the morning) and an evening single dosing regimen, taking the drug and other liquids should be stopped at least 1 hour before the start of the procedure. With the morning single dose regimen, taking the drug should be stopped no less than 2 hours, and other fluids should be taken not less than 1 hour before the procedure begins. Patients need to consider the appropriate time interval for a trip to the clinic for the procedure. You should not eat solid food with the beginning of taking the drug Moviprep and until the end of the clinical procedure.
Diarrhea is an expected effect in the preparation of the intestines. Due to the nature of the effect of the drug during the preparation of the intestine for the procedure, undesirable effects are observed in most patients. Despite some differences in specific cases, the most common undesirable effects are nausea, vomiting, abdominal distension, abdominal pain, irritation of the anus, and sleep disorders. Diarrhea and / or vomiting may cause dehydration. As with other products that include macrogol, various allergic reactions are possible, including rash, urticaria, pruritus, angioedema, and anaphylactic shock. Unwanted effects are classified according to the frequency : very often (≥1 / 10), often (≥1 / 100, <1/10), infrequently (≥1 / 1000, <1/100), rarely (≥1 / 10 000, <1/1 000) , very rarely (<1/10 000),frequency unknown (impossible to estimate based on the data obtained). From the immune system: frequency unknown - allergic reactions, including anaphylactic reactions, dyspnea and skin reactions. Mental disorders: often - sleep disorders. From the nervous system: often - dizziness, headache , frequency is unknown - convulsions associated with acute hyponatremia. On the side of metabolism: frequency is unknown - dehydration, electrolyte disturbances, including a decrease in the level of bicarbonate in the blood, hypercalcemia and hypocalcemia , hypophosphatemia, hypokalemia and hyponatremia and changes in the levels of chlorides in the blood. Cardiovascular system: frequency unknown - short-term increase in blood pressure, arrhythmia, rapid heartbeat. From the gastrointestinal tract: very often - abdominal pain, nausea, bloating , irritation of the anus, often - vomiting, dyspepsia, infrequently - difficulty swallowing, frequency unknown - flatulence, urge to vomit. On the side of the liver and biliary tract: infrequently - abnormalities of functional liver samples. Our skin and subcutaneous tissues: frequency unknown - allergic skin reactions, including angioedema, urticaria, itching, rash and redness of the skin. Common reactions: very often - indisposition, fever, often - chills, thirst, hunger, rarely - discomfort. If any of the above undesirable effects are aggravated, or the patient has noticed any other undesirable effects, he should inform the physician.
Interaction with other drugs
Diarrhea caused by the administration of Moviprep can lead to impaired absorption of other concomitant medications. Drugs taken orally within one hour prior to the onset of the laxative effect of the drug (for example, oral contraceptives) can be removed from the gastrointestinal tract without being absorbed.
Contraindications to use: - hypersensitivity to any of the components of the drug, - violation of gastric emptying (gastroparesis), - intestinal obstruction, - perforation or the risk of perforation of the digestive tract, - phenylketonuria (due to the content of aspartame), - glucose deficiency-6- phosphate dehydrogenase (due to the content of ascorbic acid) - severe inflammatory bowel disease or toxic megacolon, which is a complication of pronounced inflammatory processes in the intestine,including Crohn's disease and ulcerative colitis, - age up to 18 years, - unconsciousness. With caution - impaired gag reflex, tendency to aspiration or regurgitation, - impaired consciousness, - dehydration, - severe heart failure (III-IV FC according to the NYHA classification) , - severe renal failure (CK <30 ml / min), - severe acute inflammatory diseases, - abdominal pain of unknown etiology, - risk of arrhythmia, for example, patients receiving treatment for cardiovascular diseases or having diseases of the shield hydrochloric zhelezy.Pri presence of one of the diseases listed before taking MOVIPREP patient should consult with a physician is required.